Journal: Molecular Cancer

Article Title: Regulatory mechanisms of PD-1/PD-L1 in cancers

doi: 10.1186/s12943-024-02023-w

Figure Lengend Snippet: The regulation of PD-1/PD-L1 signaling on immune cells. a . The PD-1/PD-L1 pathway promotes the exhaustion and apoptosis of effector T cells. Tex cells are characterized by increased expression of highly inhibitory receptors, including PD-1, LAG3, and TIGIT, decreased cytokine production such as TNF, IL-2, and IFN-γ, metabolic alterations, and impaired proliferative capacity and survival. b . PD-1/PD-L1 promotes the generation and development of induced Tregs (iTregs) by reducing the phosphorylation of PI3K/Akt/mTOR and S6, while enhancing PTEN, thus enhancing the immune suppression functions of Treg cells and inducing immune tolerance. c . PD-1/PD-L1 can promote the polarization of tumor-associated macrophages (TAM) toward the M2 phenotype, releasing large amounts of fibroblast growth factor, VEGF, TNF-α, and other cytokines to promote angiogenesis and support immune suppression, invasion, and metastasis of cancer cells, accelerating cancer progression. d . PD-1 on NK cells binds to PD-L1 on cancer cells, inhibiting the degranulation and cytotoxic function of NK cells, decreasing their ability to kill tumor cells, and promoting tumor immune escape. The use of PD-1 and PD-L1 inhibitors may reactivate the anti-tumor immune response of the above immune cells. Figure created with BioRender

Article Snippet: Currently, the therapeutic approaches targeting PD-1/PD-L1 include immune checkpoint inhibitors, adoptive T cell therapy (ACT), gene editing therapies, and tumor vaccines, which have been widely applied clinically in advanced cancer patients, particularly in melanoma and lung cancer, achieving remarkable early success and greatly improving the overall survival and progression-free survival of cancer patients [ ].

Techniques: Expressing, Phospho-proteomics

Journal: Bone Marrow Transplantation

Article Title: The 46 th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Poster Session (P001-P706)

doi: 10.1038/s41409-020-01120-w

Figure Lengend Snippet:

Article Snippet: Chiara Bonini received research founding by Intellia Therapeutics, is owner of patents in the field of adoptive T-cell therapy and is a consultant of Molmed Spa, Intellia therapeutics, TxCell, Novartis, GSK, Allogene and Kite/Gilead.

Techniques: